2026-10-29 22:04:41 UTC#541320newconfirmednews
Pharming Group N.V. stock news
Pharming Group N.V. stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-27 12:27:02 UTC#521169newconfirmednews
Pharming Group Q3 2026 earnings call begins
2026-10-27 07:01:08 UTC#519120duplicateconfirmednews
Pharming Group N.V. reports Q3 adjusted EPS of 3 cents and revenue of $117.56 million
2026-10-27 06:11:07 UTC#518927duplicateconfirmednews
Pharming Group Q3 revenue up 21% on US demand; tightens 2026 revenue guidance to $380M-$390M
2026-10-27 06:04:27 UTC#518900updateconfirmeddata release
Pharming Group reports 9M net income of $18.9M, operating profit of $26.3M and Q3 EPS of $0.032
2026-10-27 06:00:00 UTC#518867newconfirmednews
Pharming Group Q3 revenue rises 21% to $117.6M, beats expectations; tightens 2026 revenue guidance to $380M-$390M
2026-10-22 05:00:00 UTC#497525newconfirmednews
Pharming Group reports Q3 2026 revenue of $117.6M, up 21% YoY; tightens FY 2026 revenue guidance to $380M-$390M
2026-10-14 06:00:00 UTC#456870duplicateconfirmednews
Pharming presents positive Phase II data for leniolisib in genetic PIDs at ESID 2026
globenewswireimportance 0.40trust 0.90Pharming Group N.V. +0.60leniolisib +0.60European Society for Immunodeficiencies 0+1 entities
2026-10-14 06:00:00 UTC#456868newconfirmednews
Pharming Group reports positive Phase II topline data for leniolisib in genetic PIDs; CVID data due in November
2026-09-29 05:04:44 UTC#381767duplicateconfirmednews
Pharming Group CEO Fabrice Chouraqui steps down; CCO and CFO named interim co-CEOs
2026-09-29 05:00:00 UTC#381733duplicateconfirmedpress release
Pharming CEO Fabrice Chouraqui steps down; CCO Leverne Marsh and CFO Kenneth Lynard named interim co-CEOs
globenewswireimportance 0.40trust 1.00Pharming Group N.V. -0.30Fabrice Chouraqui -0.20Leverne Marsh 0+1 entities
2026-09-29 05:00:00 UTC#381732newconfirmedpress release
Pharming CEO Fabrice Chouraqui steps down; CCO Leverne Marsh and CFO Kenneth Lynard named interim co-CEOs
dow_jonesimportance 0.60trust 1.00Pharming Group N.V. -0.30Fabrice Chouraqui -0.20Leverne Marsh 0+1 entities
2026-09-25 14:36:31 UTC#369378duplicateconfirmednews
Pharming Group's sNDA for lower-dose Joenja in pediatric APDS accepted for FDA priority review
reutersimportance 0.30trust 0.90Pharming Group N.V. +0.50Joenja +0.50Food and Drug Administration +0.50+1 entities
2026-09-25 14:30:00 UTC#369361duplicateconfirmedpress release
Pharming sNDA for lower-dose Joenja in pediatric APDS accepted for FDA Priority Review with Jan 30, 2027 PDUFA date
globenewswireimportance 0.30trust 1.00Pharming Group N.V. +0.40U.S. Food and Drug Administration +0.40Joenja +0.40+2 entities
2026-09-25 14:30:00 UTC#369360newconfirmednews
Pharming Group's Joenja sNDA for pediatric APDS receives FDA Priority Review with Jan 30, 2027 PDUFA date
tradingviewimportance 0.50trust 0.70Pharming Group N.V. +0.50Food and Drug Administration +0.40Joenja +0.50
2026-09-22 16:17:27 UTC#350297newconfirmednews
H.C. Wainwright reiterates Buy rating on Pharming, maintains $37 price target
tradingviewimportance 0.40trust 0.60H.C. Wainwright & Co. 0Pharming Group N.V. +0.50leniolisib +0.50
2026-09-22 05:02:05 UTC#346473newconfirmednews
Pharming Group reports positive Phase II topline data for Leniolisib in PIDs with immune dysregulation
reutersimportance 0.40trust 0.80Pharming Group N.V. +0.60Leniolisib +0.60European Society for Immunodeficiencies 0
2026-09-15 06:36:23 UTC#311977newconfirmednews
Pharming Group projects $375–395M revenue for 2026, cites Joenja and RUCONEST growth
2026-09-11 19:27:17 UTC#300463updateconfirmednews
Pharming Group to launch newly approved Joenja doses in October
2026-09-11 16:08:09 UTC#299758newconfirmednews
FDA approves Pharming's Joenja (leniolisib) for children aged 4-11 with APDS
reutersimportance 0.50trust 0.90U.S. Food and Drug Administration 0Pharming Group N.V. +0.60Leniolisib +0.60+1 entities